Reinventing Target Discovery in Autoimmune Neuromuscular Disease: Overcoming Model Limitations, Data Gaps & Translational Risk
- Improve disease relevance of discovery models by addressing limitations of primary, iPSC‑derived, and immortalised cell systems to strengthen early target validation
- Leverage integrated multi‑omics and AI‑driven analytics to enable robust pathway analysis and informed hit prioritization prior to wet‑lab screening
- Align early assay readouts with clinical biomarkers to improve translational relevance and reduce late‑stage failure in neuromuscular programs